THE EFFECTS OF THE PART D DOUGHNUT HOLE ON MEDICARE PATIENTS WHO REQUIRE HIGH-COST MEDICATIONS

Author(s)

Dominick Esposito, PhD, Researcher/Economist1, Margaret Colby, MPP, Research Analyst2, Daniel E. Ball, Dr, PH, MBA, B, Outcomes Research Consultant3, Susan B. Garavaglia, PhD, Sr. Director Outcomes Research4, Eric Meadows, PhD, Associate Outcomes Research Consultant3, Martin D. Marciniak, MPP, PhD, Outcomes Manager31Mathematica Policy Research, Inc, Princeton, NJ, USA; 2 Mathematica Policy Research, Inc, Washington, DC, USA; 3 Eli Lilly and Company, Indianapolis, IN, USA; 4 Medco Health Solutions, Inc., Franklin Lakes, NJ, USA

OBJECTIVES To examine the effects of the Medicare Part D doughnut hole on patients who require treatment with high-cost medications. METHODS Using 2007 pharmacy claims from Medco Health Solutions, Inc., we used logistic regression analysis to examine the likelihood that patients' spending reached the doughnut hole ($2400) or catastrophic coverage ($5451), or total drug spending equivalents, for beneficiaries (enrolled for at least 6 months) with claims for cancer (N=32,625), osteoporosis (N=331,337), or rheumatoid arthritis (RA; N=5,712) medications. A comparison group with other chronic conditions (N=368,784) was matched to the study population by age, gender, geography, chronic disease score, and low-income subsidy (LIS) eligibility. Explanatory variables included plan type, coverage gap exposure, disease type, and demographic characteristics. RESULTS Compared to patients with other chronic conditions (55%), patients with cancer (79%), RA (92%), or osteoporosis (58%) had higher odds of reaching the doughnut hole compared to patients with other chronic conditions (Odds Ratios [OR] = 19.3, 32.1, and 2.1, respectively, p<0.01 for all). A similar pattern of increased odds was observed for reaching catastrophic coverage (OR cancer = 5.2, RA = 34.5, osteoporosis = 1.4, p<0.01). Compared with standard prescription drug plan (PDP) enrollees, enhanced PDP enrollees were more (OR=1.1, p<0.01), Medicare Advantage enrollees were less (OR=0.8, p<0.01), and Retiree Drug Subsidy beneficiaries were as likely (OR=0.99, p=0.88) to reach the doughnut hole. Relative to enrollees without a coverage gap, beneficiaries with one were less likely to reach $2400 in spending (OR = 0.87, p <0.01); but were more likely to reach catastrophic coverage (OR = 3.0, p<0.01). CONCLUSIONS Regardless of drug plan, the vast majority of Medicare beneficiaries in this study with cancer and RA, and most beneficiaries with osteoporosis faced large out of pocket drug costs. For beneficiaries with these conditions, available prescription coverage may not provide adequate protection from severe financial strain.

Conference/Value in Health Info

2009-05, ISPOR 2009, Orlando, FL, USA

Value in Health, Vol. 12, No. 3 (May 2009)

Code

PMS54

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Formulary Development

Disease

Musculoskeletal Disorders, Oncology, Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×